Health
FDA flags potential rare eye-condition risk tied to GLP-1 drugs
Regulators require drugmakers to inform patients and doctors about NAION, a condition that can cause sudden vision loss.
The short version
- The FDA warned GLP-1 drugs carry a potential risk of NAION and required drugmakers to inform patients and doctors.[STAT]
- NAION reduces blood flow to the optic nerve, typically causing sudden vision loss, and has no proven treatments.[STAT]
- The requirement covers all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, plus several older diabetes medications.[NBC News]
- FDA scientists have not identified a mechanism, and the agency's review followed a 2024 study reporting higher NAION rates with semaglutide.[NBC News]
Key facts
- The FDA warned that GLP-1 drugs carry a potential risk of NAION and required pharmaceutical companies to inform patients and doctors of that risk.[STAT]
- NAION is caused by insufficient blood flow to the optic nerve, typically causes sudden vision loss, can lead to blindness in severe cases, and has no proven treatments.[STAT]
- The FDA requirement applies to all GLP-1 drugs, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, as well as several older GLP-1 diabetes medications.[NBC News]
- FDA scientists were not able to identify a mechanism for how the drugs could increase the risk of NAION.[NBC News]
- The FDA said it began examining a possible link after a 2024 JAMA Ophthalmology study found diabetes patients prescribed semaglutide were four times as likely to develop NAION as those not prescribed the drug.[NBC News]
What remains uncertain
- The FDA describes a potential increased risk of NAION with GLP-1 drugs, but the reporting does not establish a confirmed causal link or mechanism.[STAT · NBC News]
- The 2024 semaglutide finding is a study result cited by the FDA as the trigger for its review, not a regulator-confirmed conclusion.[NBC News]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.
- STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionSTAT metered
- FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindnessNBC News - Top Stories
- FDA adds rare vision-loss warning to popular GLP-1 drugsABC News - Health
- FDA adds rare vision-loss warning to popular GLP-1 drugsAssociated Press
- FDA warns of rare vision-loss side effect from GLP-1 drugsCBS News - Top Stories
- FDA Warns GLP-1s May Increase Risk of Sudden BlindnessSlashdot
- FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, ZepboundCNBC
- Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindnessBBC News - World
- FDA warns of rare eye condition causing blindness from GLP-1 weight loss medicationsThe Guardian - World